Investigational drug · Phase 2
D3S-001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors With MAPK Pathway Mutations, KRAS P.G12C.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "D3S-001"
First trial start
2022
Aug 3, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "D3S-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors With MAPK Pathway Mutations
- KRAS P.G12C
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "D3S-001" as an intervention, largest first.
D3 Bio (Wuxi) Co., LtdIndustry
NCT05410145 · 442 participants (planned) · Start Aug 3, 2022 · Primary completion Apr 2027
Drug: D3S-001; Pembrolizumab and 4 more · For: KRAS P.G12C
Sites: Orange, California; Palo Alto, California; Denver, Colorado · 52 sites in all
D3 Bio (Wuxi) Co., LtdIndustry
NCT05886920 · 67 participants (planned) · Start Jul 10, 2023 · Primary completion Aug 2028
Drug: D3S-002; D3S-001 · For: Advanced Solid Tumors With MAPK Pathway Mutations
Sites: Detroit, Michigan; New York, New York; Nashville, Tennessee · 18 sites in all
D3 Bio (Wuxi) Co., LtdIndustry
NCT07093398 · 26 participants · Start Jul 11, 2025 · Primary completion Nov 12, 2025
Drug: D3S-001 · For: Healthy Adult Volunteers
Sites: Adelaide, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases.
Bhattacharya D, Roman B, Reddy S · Cancer Gene Ther 2026
- D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial.
Cho BC, Lu S, Lee MA, et al. · Nat Med 2025
- Next-generation KRAS-G12C inhibitor D3S-001 shows promise.
Killock D · Nat Rev Clin Oncol 2025
- D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities.
Zhang J, Lim SM, Yu MR, et al. · Cancer Discov 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.